Konstantinos Tsaparikos

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models

Helen Y. Zou, Luc Friboulet, David P. Kodack et al. · Cancer Cell · 2015 · 456 citations · Full text

Drug Target, Health Sciences, Preclinical Models +10

Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice

Vincent A. Pollack, Douglas M. Savage, Deborah A. Baker et al. · Journal of Pharmacology and Experimental Therapeutics · 1999 · 430 citations

Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model

Shihao Chen, Li‐Fen Lee, Timothy S. Fisher et al. · Cancer Immunology Research · 2014 · 270 citations · Full text

Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib

Qinhua Huang, Ted W. Johnson, Simon Bailey et al. · Journal of Medicinal Chemistry · 2014 · 115 citations · Full text

Aminopyridine 8E, Tumor Biology, Kinase Domain +14

PF-03814735, an Orally Bioavailable Small Molecule Aurora Kinase Inhibitor for Cancer Therapy

Jitesh P. Jani, Joel T. Arcari, Vincent Bernardo et al. · Molecular Cancer Therapeutics · 2010 · 87 citations

Cancer Therapy, Tumor Biology, Drug Targeting +15